search
Back to results

Caudal Ropivacaine With or Without Dexmedetomidine for Post Operative Analgesia

Primary Purpose

Ropivacaine, Infraumbilical Surgery, Dexmedetomidine

Status
Completed
Phase
Not Applicable
Locations
Nepal
Study Type
Interventional
Intervention
ropivacaine with dexmedetomidine
Ropivacaine with placebo
Sponsored by
National Academy of Medical Sciences, Nepal
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Ropivacaine focused on measuring ropivacaine, caudal ropivacaine, dexmedetomidine, placebo, analgesia, infraumbilical surgery

Eligibility Criteria

2 Years - 7 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Children of either sex aged 2-7 years ASA (American Society of Anesthesiologist) physical status I or II Patients undergoing elective infraumbilical surgeries Exclusion Criteria: History of neuromuscular or psychiatric disease Coagulation disorders Skin lesion at the site of injection Spine deformity History of developmental delay Allergy to study drugs

Sites / Locations

  • National Academy of Medical Sciences (NAMS)

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Ropivacaine with dexmedetomidine

Ropivacaine with Normal Saline

Arm Description

Outcomes

Primary Outcome Measures

Duration of analgesia:
The primary outcome will be the duration of analgesia defined as the time period between administration of study drugs to first need of rescue analgesia when until the time of rFLACC score (revised Face, Legs, Activity, Cry, and Consolability) reached ≥4.
Post-operative pain Assessment (rFLACC score) rFLACC score (revised Face, Legs, Activity, Cry, and Consolability)
Each of the five categories F (face), L (legs), A (Activity), C (Cry), C (Consolability) will be scored from 0 to 2 which results total score in between zero and ten.
Total analgesics consumption in first 24 hours postoperative period
If r-FLACC pain score ≥4 at any time, an injection Paracetamol 15mg/kg will be given. If the r-FLACC pain score still ≥4 after 30 minutes of injection Paracetamol, then the child will treated with an injection Pethidine 0.5mg/kg. After that, an injection Paracetamol at 15mg/kg will be given 6 hourly. Total analgesic consumption in the first 24 hours will be calculated by adding the total analgesic consumed in 24 hours after the intervention.

Secondary Outcome Measures

Side effects of study drugs
Adverse events such as nausea, vomiting, bradycardia, respiratory depression and urinary retention will be monitored for 24 hours and treated accordingly

Full Information

First Posted
July 21, 2023
Last Updated
July 29, 2023
Sponsor
National Academy of Medical Sciences, Nepal
search

1. Study Identification

Unique Protocol Identification Number
NCT05979558
Brief Title
Caudal Ropivacaine With or Without Dexmedetomidine for Post Operative Analgesia
Official Title
Study of Caudal Ropivacaine With or Without Dexmedetomidine for Postoperative Analgesia in Pediatric Infra-umbilical Surgery: A Double-blinded Randomized Control Trial
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Completed
Study Start Date
June 16, 2020 (Actual)
Primary Completion Date
June 10, 2021 (Actual)
Study Completion Date
December 10, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
National Academy of Medical Sciences, Nepal

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The goal of this clinical trial is to evaluate the postoperative analgesic effects of caudal Ropivacaine with or without Dexmedetomidine in pediatric infraumbilical surgery. The main question[s] it aims to answer are: • if Caudal Dexmedetomidine with Ropivacaine would prolong the duration of analgesia in children undergoing infraumbilical surgery. Participants will receive ropivacaine with dexmedetomidine in infraumbilical surgery. If there is a comparison group: Investigators will compare this with ropivacaine with a placebo to see if the duration of analgesia differs.
Detailed Description
Children have significant pain following surgery. It has been under-managed most of the time. Poorly controlled post-operative pain increases the morbidity. It leads to post-operative agitation, urinary retention, nausea and vomiting, hypoxia, pulmonary edema, cardiovascular and temperature instability. So, postoperative pain management is an essential and important component of pediatric postoperative care. Adequate pain control after surgery permits early mobilization, reduces postoperative complication, prevents development of fear and anxiety and allows early hospital discharge. Caudal block is one of the modality of multimodal analgesia. It is a well-established, effective and relatively safe technique used for intra and post-operative analgesia in children undergoing abdominal and lower limb surgery. It provides excellent analgesia, reduces intra-operative anesthetics drug requirements, ensures pain free recovery from anesthesia, decreases stress response and avoids deleterious adverse effects of narcotic drugs. However, the main disadvantage of caudal block is being its short duration of action with sole local anesthetics. Even long-acting local anesthetic drugs such as bupivacaine provides only 4-8 hours of analgesia. The insertion of catheter in caudal space to administer repeated doses or continuous infusions of local anesthetic drug is not popular because of concerns of infection. So, various adjuvants like Fentanyl, Morphine, Ketamine, clonidine, Dexmeditomidine etc. have been used to prolong the duration of analgesia. Morphine and Fentanyl are opioids that have been used traditionally in combination with a local anesthetic to achieve prolonged anesthetic effect. The addition of opioid does provide better analgesia but there is a possibility of an increased incidence of pruritus, urinary retention, nausea, vomiting and respiratory depression. Similarly, Ketamine and Clonidine are the widely preferred adjuvant to caudal block but have their own number of unpleasant adverse effects8. Hence, there is still ongoing investigations to find for an adjuvant that can safely prolong caudal analgesia. Recently, Dexmedetomidine has been used for this purpose. Various studies have described the use of Dexmedetomidine with local anesthetic drugs in caudal block for the management of postoperative pain in children. Saadawy et al. found that 1μg/kg caudal dexmedetomidine with bupivacaine was associated with an extended duration of postoperative analgesia while in other studies 2μg/kg Dexmedetomidine was used with caudal Bupivacaine or Ropivacaine for providing postoperative analgesia in children undergoing lower abdominal and perineal surgeries. Dexmedetomidine is a highly specific and selective α2-adrenoceptor agonist that has been described as a safe and effective additive in many anesthetic procedures. In contrast to other agents, it has a sympatholytic, analgesic and sedative effects. It is remarkably free from side effects except for hypotension and bradycardia. But studies investigating its analgesic property in our population are limited. Ropivacaine is a long-acting amino amide local anesthetic drug and was the first to be formulated as a pure S-enantiomer. It is reported to have a better safety profile than Bupivacaine with less risk for central nervous system and cardiac toxicity 10. It also decreases unwanted motor block than Bupivacaine, which makes it a more suitable agent for caudal epidural analgesia6. Dexmedetomidine with Ropivacaine is commonly used to prolong the caudal analgesia in western population but have not been well studied in our pediatric population. So investigators designed this study to determine analgesic effect of caudal Dexmedetomidine with Ropivacaine in pediatric infraumbilical surgeries. HYPOTHESIS Caudal Dexmedetomidine with Ropivacaine would not prolong the duration of analgesia in children undergoing infraumbilical surgery. GENERAL OBJECTIVES To evaluate the postoperative analgesic effects of caudal Ropivacaine with or without Dexmedetomidine in pediatric infraumbilical surgery SPECIFIC OBJECTIVES To compare rFLACC score (revised Face, Legs, Activity, Cry, and Consolability)in 24 hours of postoperative period. To compare the time for first rescue analgesia. To evaluate the total analgesics consumption in 24 hours of postoperative period. To observe the side effects of study drugs (vomiting and bradycardia).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ropivacaine, Infraumbilical Surgery, Dexmedetomidine, Analgesia
Keywords
ropivacaine, caudal ropivacaine, dexmedetomidine, placebo, analgesia, infraumbilical surgery

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Children were randomly assigned to two groups having 31 children in each, by using a computer-generated table of random numbers which was enclosed in a sealed envelope and was opened by an anesthesiologist who were not involved in the study.
Masking
ParticipantCare Provider
Masking Description
Children were randomly assigned to two groups having 31 children in each, by using a computer-generated table of random numbers which was enclosed in a sealed envelope and was opened by an anesthesiologist who were not involved in the study.
Allocation
Randomized
Enrollment
62 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Ropivacaine with dexmedetomidine
Arm Type
Experimental
Arm Title
Ropivacaine with Normal Saline
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
ropivacaine with dexmedetomidine
Intervention Description
this group received with ropivacaine with dexmedetomidine
Intervention Type
Drug
Intervention Name(s)
Ropivacaine with placebo
Intervention Description
this group received with ropivacaine with normal saline
Primary Outcome Measure Information:
Title
Duration of analgesia:
Description
The primary outcome will be the duration of analgesia defined as the time period between administration of study drugs to first need of rescue analgesia when until the time of rFLACC score (revised Face, Legs, Activity, Cry, and Consolability) reached ≥4.
Time Frame
upto first 24 hour after intervention
Title
Post-operative pain Assessment (rFLACC score) rFLACC score (revised Face, Legs, Activity, Cry, and Consolability)
Description
Each of the five categories F (face), L (legs), A (Activity), C (Cry), C (Consolability) will be scored from 0 to 2 which results total score in between zero and ten.
Time Frame
first 24 hour after intervention
Title
Total analgesics consumption in first 24 hours postoperative period
Description
If r-FLACC pain score ≥4 at any time, an injection Paracetamol 15mg/kg will be given. If the r-FLACC pain score still ≥4 after 30 minutes of injection Paracetamol, then the child will treated with an injection Pethidine 0.5mg/kg. After that, an injection Paracetamol at 15mg/kg will be given 6 hourly. Total analgesic consumption in the first 24 hours will be calculated by adding the total analgesic consumed in 24 hours after the intervention.
Time Frame
first 24 hours after intervention
Secondary Outcome Measure Information:
Title
Side effects of study drugs
Description
Adverse events such as nausea, vomiting, bradycardia, respiratory depression and urinary retention will be monitored for 24 hours and treated accordingly
Time Frame
monitored for 24 hours and treated accordingly

10. Eligibility

Sex
All
Minimum Age & Unit of Time
2 Years
Maximum Age & Unit of Time
7 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Children of either sex aged 2-7 years ASA (American Society of Anesthesiologist) physical status I or II Patients undergoing elective infraumbilical surgeries Exclusion Criteria: History of neuromuscular or psychiatric disease Coagulation disorders Skin lesion at the site of injection Spine deformity History of developmental delay Allergy to study drugs
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kaushal Tamang, MBBS,MD
Organizational Affiliation
NAMS
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Bidur K Baral, MBBS,MD
Organizational Affiliation
NAMS
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Sadichhya S Malla, MBBS,MD
Organizational Affiliation
Kanti Hospital
Official's Role
Study Chair
Facility Information:
Facility Name
National Academy of Medical Sciences (NAMS)
City
Kathmandu
State/Province
Bagmati
ZIP/Postal Code
44600
Country
Nepal

12. IPD Sharing Statement

Learn more about this trial

Caudal Ropivacaine With or Without Dexmedetomidine for Post Operative Analgesia

We'll reach out to this number within 24 hrs